Axsome Initiates Solriamfetol ADHD Trial
Analysis based on 16 articles · First reported Jun 26, 2026 · Last updated Jun 26, 2026
The initiation of the FOCUS-3 Phase 3 trial by Axsome Therapeutics for Solriamfetol in adolescents with Attention deficit hyperactivity disorder could positively impact the company's stock if the trial yields favorable results, potentially expanding its market share in CNS disorders. This development signals a potential new revenue stream for Axsome Therapeutics and offers a new treatment option for a condition with a significant patient population.
Axsome Therapeutics has announced the initiation of its FOCUS-3 Phase 3 trial for Solriamfetol, a drug being developed to treat Attention deficit hyperactivity disorder in adolescents aged 12 to less than 18 years. The trial is a randomized, double-blind, placebo-controlled, multicenter study involving approximately 468 patients over 6 weeks. The primary endpoint will be the change from baseline to week 6 in the ADHD Rating Scale (ADHD-RS-5) total score. Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT1A agonist, also being developed for other conditions like major depressive disorder with excessive daytime sleepiness, binge eating disorder, and excessive sleepiness associated with shift work disorder. This trial represents a significant step for Axsome Therapeutics in expanding its neuroscience portfolio.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard